期刊文献+

供、受者ABO血型不相容保留受者脾脏的亲属活体供肾移植一例 被引量:19

原文传递
导出
摘要 器官移植中,一般遵循供、受者ABO血型相同或相容的原则,然而,为了充分利用供者资源,以缓解日趋紧张的供需矛盾,有人尝试在ABO血型不相容者间进行器官移植,且已有成功的报道^[1-3]。我们于2006年12月为1例肾功能衰竭患者施行供、受者ABO血型不相容的亲属活体供。肾移植,目前受者存活,能从事一般劳动。
出处 《中华器官移植杂志》 CAS CSCD 北大核心 2007年第11期694-695,共2页 Chinese Journal of Organ Transplantation
  • 相关文献

参考文献10

  • 1Tanabe K, Takahashi K, Sonda K, et al. Long-term results of ABO-incompatible living kidney transplantation: a singlecenter experience. Transplantation, 1998, 65(2):224-228.
  • 2Takahashi K, Saito K, Takahara S, et al. Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant, 2004, 4(7) : 1089-1096.
  • 3Takahashi K, Saito K, Tanabe K, et al. First report of a 7- year survey on ABO-incompatible kidney transplantation in Japan. Clin Exp Nephrol, 2001, 5(1 ) : 119-125.
  • 4Knoll GA, Bell RC. Taerolimus versus eyelosporin for immunosuppression in renal transplantation: meta-analysis of randomized trials. BMJ, 1999, 318(7191) :1104-1107.
  • 5Margreiter R. Efficacy and safety of tacrolimus compared with cyclosporin microemulsion in renal transplantation: a randomized multicentre study. Lancet, 2002, 359(9308):741-746.
  • 6Alexandre GP, Squifflet JP, De Bruyere M, et al. Spleneetomy as a prerequisite for successful human ABO-incompatible renal transplantation. Transplant Proe, 1985, 17 (2): 138- 143.
  • 7Ishida H, Furusawa M, Murakami T, et al. Outcome of an ABO-incompatible renal transplant without splenectomy. Transplant Int, 2002, 15(1) :56-58.
  • 8Winters JL, Gloor GM, Pineda AA, et al. Plasma exchange conditioning for ABO-incompatible renal transplantation. J Clin Apheresis, 2004, 19(9) :79-85.
  • 9Tyden G, Kumlien G, Genberg H, et al. ABO-incompatible renal transplantation without splenectomy, using antigenspecific immunoadsorption and rituximab. Am J Transplant,2005, 5(1):145-148.
  • 10Sonnenday CJ, Warren DS, Cooper M, et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow AEO- incompatible renal transplantation without splenectomy. Am J Transplant, 2004, 4(8):1315-1322.

同被引文献76

  • 1张勇,熊盛道.肾移植术后肺部感染的诊治进展[J].中华医院感染学杂志,2006,16(4):475-477. 被引量:11
  • 2Tvdén G,Donauer J,Wadsrom J,et al.Implementation of a Protocol for ABO-incompatible kidney transplantation-a three-center experience with 60 consecutive transplantations[J].Transplantation,2007,83(9):1153-1155.
  • 3Maloney DG, Liles TM, Czerwinski DK,et al. Phase I clinical trial using escalating single - dose infusion of chimeric anti - CD20 monoclonal antibody ( IDEC - C2B8 ) in patients with recurrent B - cell lymphoma. Blood 1994 ;84:2457 - 2466.
  • 4Schriever F, Freedman AS, Freeman G, et al. Isolated human follicular dendritic cells display a unique antigenic phenotype. J Exp Med, 1989,169:2043 - 2058.
  • 5Fishelson Z, Donin N, Zell S, et al. Obstacles to cancer immuno- therapy:Expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol,2003 ;40 : 109 - 123.
  • 6Harjunp A, Jurmikkala S, Meri S. Rituximab ( anti - CD20) ther- apy of Bcell lymphomas: Direct complement killing is superior to cellular effectar mechanisms. Scand J Immunol 2000 ; 51 : 634 - 641.
  • 7Coiffier B, Haioun C, Ketterer N, et al. Rituximab ( anti - CD20 monoclonalantibody) for the treatment of patients with relapsing or- refractory aggressive lymphoma: a multicenter phase II study. Blood 1998 ;92 : 1927 - 1932.
  • 8OBrien SM, Kantarjina H, Thomas DA, et al. Rituximab dosees- calation trial in chronic lymphocytic leukaemia. J Clin Oncol 2001 ; 19:2165 - 70.
  • 9Guillaume Cartron, Blasco H, Palntand Get al. Pharmacokineties of Rituximab and its clinical use:Thought for the best use? Critical Reviews in Oncology/Hematology 62 (2007) 43 - 52.
  • 10Vieira CA, Agarwal A, Book BK, et al. Rituximab for reduction of anti - HLA antibodies in patients awaiting renal transplantation : 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004 ;77:542.

引证文献19

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部